Scarica l'app Stockscreener
12.06
1.94%
0.23
Dopo l'orario di chiusura:
12.05
-0.010
-0.08%
Precedente Chiudi:
$11.83
Aprire:
$12.08
Volume 24 ore:
3.83M
Relative Volume:
0.86
Capitalizzazione di mercato:
$1.25B
Reddito:
$45.97M
Utile/perdita netta:
$-508.80M
Rapporto P/E:
-2.2007
EPS:
-5.48
Flusso di cassa netto:
$-382.65M
1 W Prestazione:
+4.55%
1M Prestazione:
+25.63%
6M Prestazione:
+26.95%
1 anno Prestazione:
-53.78%
Intervallo 1D:
$11.86
$12.55
Intervallo di 1 settimana:
$11.30
$12.55
Portata 52W:
$5.90
$27.42
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Nome
Intellia Therapeutics Inc
Settore
Industria
Telefono
857-285-6200
Indirizzo
40 ERIE STREET, CAMBRIDGE, MA
Confronta NTLA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
12.06 | 1.19B | 45.97M | -508.80M | -382.65M | -5.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.81 | 120.40B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.52 | 61.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.53 | 41.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
564.59 | 34.29B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.55 | 27.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-21 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-03-05 | Iniziato | H.C. Wainwright | Buy |
| 2025-02-28 | Downgrade | Goldman | Neutral → Sell |
| 2025-02-28 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-01-27 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-23 | Downgrade | Goldman | Buy → Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-04-13 | Iniziato | Canaccord Genuity | Buy |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-03-14 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-02-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-01-24 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-01-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-11 | Iniziato | Morgan Stanley | Overweight |
| 2022-09-21 | Iniziato | JP Morgan | Overweight |
| 2022-09-01 | Iniziato | Citigroup | Sell |
| 2022-06-17 | Iniziato | BMO Capital Markets | Market Perform |
| 2022-06-16 | Iniziato | BofA Securities | Buy |
| 2022-04-28 | Iniziato | Credit Suisse | Outperform |
| 2022-02-18 | Iniziato | William Blair | Outperform |
| 2022-02-07 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-01-31 | Iniziato | Cowen | Outperform |
| 2022-01-07 | Iniziato | Piper Sandler | Overweight |
| 2021-10-05 | Iniziato | Guggenheim | Buy |
| 2021-09-24 | Iniziato | Stifel | Buy |
| 2021-06-28 | Reiterato | H.C. Wainwright | Buy |
| 2021-06-11 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-07 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2021-05-04 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-03-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-12-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-10-27 | Iniziato | Truist | Buy |
| 2020-10-14 | Iniziato | Wells Fargo | Overweight |
| 2020-09-18 | Iniziato | Goldman | Buy |
| 2020-02-28 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-02-14 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-11-01 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2019-07-09 | Iniziato | Robert W. Baird | Outperform |
| 2019-06-10 | Iniziato | ROTH Capital | Neutral |
| 2019-05-03 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2018-11-02 | Downgrade | Wedbush | Outperform → Neutral |
| 2018-10-29 | Iniziato | Credit Suisse | Neutral |
| 2018-09-21 | Iniziato | Raymond James | Mkt Perform |
| 2018-05-15 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2018-03-08 | Iniziato | JMP Securities | Mkt Outperform |
| 2017-11-01 | Reiterato | Jefferies | Buy |
| 2017-06-22 | Ripresa | Jefferies | Buy |
| 2017-03-28 | Iniziato | Chardan Capital Markets | Buy |
| 2016-08-05 | Aggiornamento | Jefferies | Hold → Buy |
Mostra tutto
Intellia Therapeutics Inc Borsa (NTLA) Ultime notizie
What analysts say about Intellia Therapeutics Inc. stockOutstanding risk-reward balance - Jammu Links News
Intellia Therapeutics: A High-Volatility, High-Reward Play in the CRISPR Revolution - AInvest
With Intellia Therapeutics, Human Patience Beat Hot-Take Trading: Still At ‘Buy’ (NTLA) - Seeking Alpha
Intellia Therapeutics Inc. Stock Analysis and ForecastHigh-profit capital plays - Jammu Links News
Regeneron and Intellia’s Gene Therapy Study for Hemophilia B: A Market Game-Changer? - TipRanks
Intellia Faces The Biotech Balancing Act As Shares Slide - Finimize
ATTR Amyloidosis Pipeline 2025: Groundbreaking Clinical - openPR.com
Regeneron and Intellia’s Gene Therapy Study: A Potential Game-Changer for Hemophilia B - TipRanks
Intellia Therapeutics (NTLA) Soars 9.08% on Phase III Trial - AInvest
Possible Bearish Signals With Intellia Therapeutics Insiders Disposing Stock - simplywall.st
Intellia Therapeutics (NTLA) Receives a Buy from RBC Capital - The Globe and Mail
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Gene Editing Leader Intellia Expands Team with 23,800 Share RSU Grant Package - Stock Titan
Intellia Gains 29.8% in a Month: How Should You Play the Stock? - Nasdaq
Intellia Therapeutics Reports Inducement Grants under Nasdaq Lis - GuruFocus
Insider Sell: Eliana Clark Sells Shares of Intellia Therapeutics Inc (NTLA) - GuruFocus
Citizens JMP Maintains Neutral Stance on Intellia Despite Positive Lonvo-z Data - Insider Monkey
Insider Sell Alert: Jesse Goodman Sells Shares of Intellia Thera - GuruFocus
The Best Biotech Stocks to Buy - Morningstar
CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential? - Yahoo Finance
Intellia Reports Positive 3-Year Lonvo-z Data in HAE Trial at EAACI Congress. - Yahoo Finance
Will Intellia Therapeutics (NASDAQ:NTLA) Spend Its Cash Wisely? - Yahoo Finance
Intellia Therapeutics’ SWOT analysis: gene editing pioneer’s stock faces pivotal year - Investing.com
From Now to 2032: Unpacking the Genome Editing Market's - openPR.com
Gene-Editing Stocks Gain on LLY-VERV Deal Announcement - TradingView
Intellia Reports Positive Three-Year Follow-up Data from Phase 1 CRISPR Trial in Hereditary Angioedema - CRISPR Medicine News
Intellia Therapeutics, Inc. (NTLA) Backed by H.C. Wainwright for 237% Upside Potential - Yahoo Finance
Intellia’s three-year HAE treatment data shows durability, Citizens JMP says - Investing.com Canada
FDA clears CSL’s swelling disease drug; Regeneron loses 23andMe auction - BioPharma Dive
Intellia Therapeutics (NTLA) Receives Reiterated Buy Rating with Stable Price Target | NTLA Stock News - GuruFocus
Intellia Therapeutics Announces Positive Phase 1 Trial Data - TipRanks
Intellia Therapeutics Says Potential Hereditary Angioedema Treatment Reduces Attacks - MarketScreener
Intellia Therapeutics Announces Positive Three-Year Data - GlobeNewswire
Intellia Therapeutics Announces Positive Three-Year Data from Ph - GuruFocus
Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress - GlobeNewswire
Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress - GlobeNewswire Inc.
Intellia Therapeutics Reports Promising Three-Year Follow-Up Data for Lonvo-z in Hereditary Angioedema Patients - Quiver Quantitative
Intellia Therapeutics’ SWOT analysis: gene editing stock faces pivotal year - Investing.com
Intellia Therapeutics Holds Annual Stockholders’ Meeting - TipRanks
California State Teachers Retirement System Grows Stock Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) - Defense World
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | NTLA Stock News - GuruFocus
Intellia Therapeutics Expands CRISPR Team: 33,600 RSUs Granted to New Leadership - Stock Titan
Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting - mx.advfn.com
How Much Upside is Left in Intellia Therapeutics (NTLA)? Wall Street Analysts Think 398.31% - sharewise
Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline? - TradingView
Intellia Therapeutics (NASDAQ:NTLA) Given New $54.00 Price Target at Canaccord Genuity Group - Defense World
Intellia Therapeutics (NTLA) Price Target Adjusted by Canaccord Genuity | NTLA Stock News - GuruFocus
(NTLA) Investment Report - news.stocktradersdaily.com
Intellia Therapeutics (NTLA) Sees Price Target Cut Amid Study Up - GuruFocus
Intellia Therapeutics (NTLA) Sees Price Target Cut Amid Study Updates | NTLA Stock News - GuruFocus
ARK Investment Acquires 226K Shares of Intellia Therapeutics (NT - GuruFocus
Intellia Therapeutics Inc Azioni (NTLA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.59%
0.34%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):